Lv1
40 积分 2024-06-05 加入
Targeting MORF4L1-mediated DNA repair potentiates RT-induced antitumor immunity via cGAS-STING activation in hepatocellular carcinoma
2天前
已完结
BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports
26天前
已关闭
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
1个月前
已完结
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
2个月前
已完结
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
2个月前
已完结
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
4个月前
已完结
An Evidence-Based Staging System for Mucosal Melanoma: A Proposal
4个月前
已完结
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients
4个月前
已完结
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
4个月前
已完结
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
4个月前
已完结
皖公网安备34019202002308
